Two bits of news today.
Looking a touch better here over the last few days re: share price. Hope the trend continues. |
Thanks for sharing. Need to find some cash over the next 6 months to buy more. Excellent pipeline. |
New TD Research note |
Only poitics in the way.
At the end of the day the money will always win. |
And the close 2 years ago to the day was 578p! |
Trinity Delta in my inbox today: HUTCHMED’s clearly articulated strategy is delivering, with consistent clinical and commercial execution marking its continuing transition from a development stage company into a profitable commercial organisation. Growth in Oncology/ Immunology revenues, defined investment priorities, and a global partnering strategy should all contribute to achieving a FY25 breakeven target. HUTCHMED aims to expand its marketed portfolio of oncology drugs in China from three to six or seven by FY25, addressing blood disorders as well as solid tumours. First global launch of an in-house product, by partner Takeda, could occur in 2024, subject to a positive FDA approval decision in November. Our updated HUTCHMED valuation is $5.74bn ($32.95 per ADS), £4.78bn and HK$44.75n (549p or HK$51.40 per share). |
It may, at last, be a decent week for HCM: HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 29, 2023: HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (“GEJ”) adenocarcinoma patients with mesenchymal epithelial transition factor (“MET”) amplification who have failed at least two lines of standard therapies. |
Up nearly 3% in HK. With luck it will be a better week in London when the market opens again tomorrow. |
some old malaise with Hutchmed, can any news impact the shareprice. Positive news and barely anything happens, negative news and the price plummets. |
Hopefully a good week for HCM incoming:
21st August 2023 - HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
EDIT - Hmm..... Perhaps not! Down nearly 2.6% in HK. HCM is just completely out of favour at present :-( |
thanks shaker - let's hope we are onwards and upwards here - PDUFA in Nov should be a big catalyst if it goes well for Takeda |
I don't but you chose a memorable name and post frequently. If not consistently |
impressed you follow me so closely shaker..... ;o-) |
Nerd of steel 6/6/23 '' I am out, lost far too much money here.. ''
Still in and adding? De ja vu |
let's hope he's worth it in the long run! |
fek me the CEO gets 1% of the company and has presided over a share price collapse.
I'm in the wrong business.
I know he's been there 18 years - didn't realize he could be paid this much:
"There will also be equity compensation of up to US$4,440,700 per annum, including performance based and non-performance based portions. Such emoluments are determined by reference to the performance and profitability of the Company as well as his personal performance, remuneration benchmark in the industry and the prevailing market conditions. Such amounts are subject to review from time to time and proration for an incomplete year of service" |
i'm buying again, this price action is a load of rubbish.....the company is so woefully undervalued now given the excellent update last week |
this is my largest long term investment and what a nightmare it has been - I hope you are right Lauders. If they continue to execute and deliver going forward there is no reasomn why they won't be a $20bn company in a few years time - Genmab has done it, Beigene has done it (despite still being loss making). There is no reason why we cannot attract a P/S of 10 again, and a P/E of around 30...... |
When it comes to HCM, yesterday was a very good day. Long may it continue. Onwards and back towards at least 400p then back and beyond the high just beyond 600p please! |
Not a member so do not have access to the note but hopefully still a positive:
2 Aug 2023 “Citi Starts Hutchmed China Ltd (13:HK) at Buy...Citi analyst John Yung initiates ...” |
JV is worth at least $1 billion too, so the current market value is cash + jv + only circa $800m for everything else including IP which is ludicrous |
valued at 2.9 x Cash.... very undervalued |
Reassuringly,HCM was up sharply in the US yesterday (+8%)following results,closing at 238p equivalent.The UK quote remains its normal anaemic self and has little credibility until given ADR leadership. |
Down in UK and US at close of play yesterday, but quite a strong start in HK today that has weakened as the day progresses. Currently up 1.7%. Let's hope that HK/China dictate the future share price if this is the pattern! |
"Strategy has allowed HUTCHMED to conserve cash and significantly reduce costs, with a substantial cash balance of $856.2 million on June 30, 2023" |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
